Gregory A Abrahamian, M.D. (LtCol USAFR)

• Professional Background

  Education

  • 1999 - Clinical Fellowship - Organ Transplantation - Massachusetts General Hospital
  • 1999 - Clinical Fellowship - Organ Transplantation - Harvard Medical School
  • 1997 - Residency - Surgery - Wilford Hall Medical Center
  • 1996 - Residency - Surgery - Wilford Hall Medical Center
  • 1993 - Internship - Surgery - Wilford Hall Medical Center
  • 1992 - MD - Medicine - University of Texas Health Science in San Antonio
  • 1988 - BS - Environmental Health Science (cum laude) - California State University

  Appointments

  • 9/2009 - Associate Professor/Clinical - University of Texas Health Science Center, Transplant Center
  • 3/2008 - Surgical Director of the Kidney Transplant Program - University Hospital Transplant CenterSan Antonio
  • 2/2005 - Surgical Director of the Kidney Transplant Program - Christus Transplant Institute, Christus Transplant Institute
  • 2/2005 - Division Head of the Kidney Transplant Program - University of Texas Health Science Center at San Antonio, Transplant Center, San Antonio
  • 6/2000 - Staff - Christus Santa Rosa Medical Center, Transplant Center, San Antonio

• Instruction & Training

  • 7/2014 - Present, Individual Instruction, UT Health
  • 4/2005 - Present, Transplant Morbidity and Mortality Conference, UT Health
  • 4/2005 - Present, UTHSCSA
  • 5/2001 - Present, Rotation Student Supervision, University Hospital
  • 5/2001 - Present, Post Graduate Rotation Supervision
  • 4/2001 - Present, Post Graduate Rotation Supervision, University Hospital
  • 5/2000 - Present, Liver/Renal Transplant-univ Hosp, The University of Texas Health Science Center
  • 5/2000 - Present, Liver/Renal Transplant-univ Hosp, The University of Texas Health Science Center

• Research & Grants

  Research profile

  Grants

  Private

  Funding Agency Roche Title An open-label, prospective, randomized, controlled, multicenter study assessing fixed dose vs concentration controlled cellcept regimens for patients following a single organ renal transplantation in combination with full dose and reduced dose calcineuri Status Active Period 4/2004 - Present Role Principal Investigator Grant Detail   Funding Agency Roche Title Mycophenolate mofetil in treatment of hepatitis C virus infection Status Complete Period 6/2002 - 1/2029 Role Co-Investigator Grant Detail   Funding Agency Astellas Pharma Global Development Title Astellas CMV Status Complete Period 1/2014 - 4/2016 Role Principal Investigator Grant Detail A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ from a CMV-Seropositive Donor Protocol for Phase 2 Study of ASP0113

• Publications

  Journal Article

  Jay C, Pugh J, Halff G, Abrahamian G, Cigarroa F, Washburn K. Graft quality matters: Survival after simultaneous liver-kidney transplant according to KDPI Clinical Transplantation 2017 Mar;. Fiorentino TV, Owston M, Abrahamian G, La Rosa S, Marando A, Perego C, Di Cairano ES, Finzi G, Capella C, Sessa F, Casirahi F, Paez An, Adivi A, Davalli A, Fiorina P, Mendoza RG, Comuzzie AG, DeFronzo RA, Halff G, Dick EJ, Folli F. Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates (Baboons: Papio Hamadryas) Am J Pathology 2015 Jan;185:139-150.

• Clinical

  Provider profile

  Board Certifications

  • American Board of Surgery